C4 Therapeutics reported Q1 2026 results highlighting progress in developing cemsidomide for multiple myeloma, including ongoing Phase 2 and Phase 1b trials and plans for a new combination trial in 2027. The company expanded its partnership with Roche to develop degrader-antibody conjugates for cancer treatment and holds $268.3 million in cash, funding operations through 2028. Despite a slight revenue decline due to collaboration changes, C4 remains focused on advancing targeted protein degradation therapies. Upcoming milestones include data presentations at major oncology conferences and further clinical trial updates.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
